Latest Regulatory News

Helios Energy has made significant strides in transitioning from exploration to production at its Presidio Project in Texas, supported by a $2.6 million capital raise and strategic U.S. hires. Early oil recovery and positive engagement with partners underscore its growing momentum.

Titanium Sands Limited has secured retention licenses for four critical exploration areas and is progressing its Environmental Impact Assessment in Sri Lanka, while engaging government officials and local landowners to navigate regulatory hurdles.

Echelon Resources finalised its EP145 acquisition and reported a slight dip in production volumes, while Amadeus Basin receipts surged 24% thanks to new wells. The company maintains a strong cash position and is actively reshaping its portfolio for future growth.

Lithium Universe Limited has secured global rights to a breakthrough solar panel recycling technology that promises to unlock vast reserves of critical minerals, while advancing its Québec lithium refinery with robust financials and strategic partnerships.

Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.

Silver Mines Limited progresses regulatory approvals for its flagship Bowdens Silver Project in NSW while acquiring promising US assets, enhancing its exploration pipeline with minimal upfront costs.

Alexium International Group faced a tough FY25 with declining sales amid a soft US mattress market but is poised for growth in FY26 thanks to technological advances and strategic funding support.

INOVIQ Limited reports breakthrough results for its ovarian cancer screening test achieving perfect early-stage detection, alongside promising advances in its CAR-exosome cancer therapy program.

Sunstone Metals reports promising exploration results from its Ecuadorian gold-copper projects alongside ongoing strategic discussions with multiple parties in a buoyant M&A environment.

Nyrada reports successful completion of five cohorts in its Phase I trial of Xolatryp with no safety concerns, alongside compelling preclinical neuro- and cardioprotective data. A Phase IIa trial targeting heart attack patients is slated for early 2026.

Kingsgate Consolidated Ltd reported a robust June quarter with Chatree Gold Mine maintaining gold production above 20,000 ounces and achieving a record All-in Sustaining Cost margin of US$1,240 per ounce. Operational efficiencies and exploration progress position the company well for FY26.

Venus Metals Corporation has made significant progress at its Bellchambers Gold Project with the granting of a mining lease and encouraging drilling results, while advancing base metals exploration at Youanmi.